# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Repare Therapeutics (NASDAQ:RPTX) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $...
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + G...
HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $10 price...
HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $10 price...